YDO1 Stock Chart & Stats
€478.70
€0.50(0.10%)
At close: 4:00 PM EDT
€478.70
€0.50(0.10%)
Day’s Range― - ―
52-Week Range€256.10 - €523.20
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00
Market Cap
€9.36B
Enterprise Value€15.16K
Total Cash (Recent Filing)€838.75M
Total Debt (Recent Filing)€347.75M
Price to Earnings (P/E)―
Beta-0.22
Next Earnings
Oct 29, 2026EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.89
Shares Outstanding23,104,126
10 Day Avg. Volume0
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)21.68
Price to Sales (P/S)13.63
P/FCF Ratio-68.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€599.37Price Target Upside25.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-6.25
Revenue Forecast (FY)€1.30B
Bulls Say, Bears Say
Bulls Say
Revenue Scale / Commercial TractionSustained rapid revenue scaling to >$1B TTM signals durable product-market fit, growing prescriber adoption and payer acceptance. This commercial momentum should provide a structural base for future margin expansion, support reinvestment in the franchise, and reduce single-launch execution risk.
High Gross Margins / Unit EconomicsExceptionally high gross margins imply strong per-unit economics and pricing power for Rezdiffra. Durable unit-level profitability allows the company to absorb elevated SG&A/R&D while scaling, improves operating leverage potential, and strengthens long-term cash generation once opex stabilizes.
Pipeline & IP ExpansionA diversified pipeline and the ARO‑PNPLA3 siRNA provide structural de-risking of a single-product model and potential new indications or combination strategies. Clinical signal in a genetically defined subgroup could create a higher-value, targeted opportunity and extend long-term commercial upside.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flow indicate ongoing reliance on financing or asset sales to fund operations and pipeline work. If revenue growth slows or gross-to-net pressure persists, the structural cash burn could force dilutive financing or constrain strategic investments over the medium term.
Rising LeverageA marked increase in leverage reduces financial flexibility and raises fixed obligations relative to equity. If operating cash flows remain negative, higher debt levels increase refinancing and interest risk, limiting the company's ability to pursue opportunistic investments or withstand adverse trial or commercial setbacks.
High Operating Expenses & Near-term UnprofitabilitySubstantially elevated R&D and SG&A to support launch, BD and DTC raise the breakeven threshold and prolong structural unprofitability. Continued high opex plus mid‑to‑high‑30% gross-to-net discounts mean realized revenue must scale materially to convert strong gross margins into sustainable net profitability.
Madrigal Pharmaceuticals News
YDO1 FAQ
What was Madrigal’s price range in the past 12 months?
Madrigal lowest stock price was €256.10 and its highest was €523.20 in the past 12 months.
What is Madrigal’s market cap?
Madrigal’s market cap is €9.36B.
When is Madrigal’s upcoming earnings report date?
Madrigal’s upcoming earnings report date is Oct 29, 2026 which is in 87 days.
How were Madrigal’s earnings last quarter?
Madrigal released its earnings results on Jul 30, 2026. The company reported -€1.725 earnings per share for the quarter, beating the consensus estimate of -€2.32 by €0.595.
Is Madrigal overvalued?
According to Wall Street analysts Madrigal’s price is currently Undervalued.
Does Madrigal pay dividends?
Madrigal does not currently pay dividends.
What is Madrigal’s EPS estimate?
Madrigal’s EPS estimate is -0.71.
How many shares outstanding does Madrigal have?
Madrigal has 23,104,126 shares outstanding.
What happened to Madrigal’s price movement after its last earnings report?
Madrigal reported an EPS of -€1.725 in its last earnings report, beating expectations of -€2.32. Following the earnings report the stock price went down -15.857%.
Which hedge fund is a major shareholder of Madrigal?
Currently, no hedge funds are holding shares in DE:YDO1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Madrigal Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€599.37 (25.21% Upside)
€599.37 (25.21% Upside)
Blogger Sentiment
Bullish
DE:YDO1 Sentiment 88%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €382.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
22.58%
Trailing 12-Months
Company Description
Madrigal
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
YDO1 Company Deck
YDO1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive commercial and scientific momentum: Rezdiffra has achieved blockbuster status with rapid patient growth, a materially expanding addressable market, and an increasingly diverse pipeline (including a promising siRNA asset). These positives are balanced by elevated operating expenses, one‑time business development costs, a material gross‑to‑net discount, and near‑term non‑profitability with cash modestly reduced by strategic uses. Management emphasized durable long‑term opportunity, upcoming outcomes milestones (2027–2028), and disciplined, data‑driven pipeline advancement.View all DE:YDO1 earnings summariesYDO1 Stock 12 Month Forecast
Average Price Target
€599.37
▲(25.21% Upside)
Technical Analysis
Exelixis
―
Ionis Pharmaceuticals
―
Ascendis Pharma
―
BridgeBio Pharma
―
Roivant Sciences
―